Analyst: Darzalex sales figures could result in Genmab upgrade
Sales of the Genmab-developed drug Darzalex, which is in-licensed to Jonhson & Johson, have gone so well in the third quarter that one analyst thinks a guidance upgrade from Genmab could likely be on its way.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
The bone marrow cancer treatment Darzalex exceeded analysts' third quarter sales expectations with around DKK 850m.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab sales of Darzalex exceed expectations in Q3
For subscribers
Genmab: Janssen dispute cost DKK 146m in H1
For subscribers
Janssen had better Darzalex sales than expected in Q1
For subscribers
.jpg&w=384&q=75)
